Home Products About Us Contact

Chromogenic Kits

Learn more about our Chromogenic Kits.

Phospholipid Emulsions

Our highly stable phospholipid emulsions are suitable for use in analyses related to procoagulant and anticoagulant pathways.


Download the references list here (pdf):

References Rossix Phospholipids

Oehmcke S, Westman J, Malmstrom J, Morgelin M, Olin AI, et al.

A Novel Role for Pro-Coagulant Microvesicles in the Early Host Defense against Streptococcus pyogenes.

PLoS Pathog 9(8), 2013: e1003529. doi:10.1371/journal.ppat.1003529

Pieters M,  Kotze RC, Jerling JC, Kruger A-M, Ariëns RAS.

Evidence that fibrinogen γ' regulates plasma clot structure and lysis, and relationship to cardiovascular risk factors in black Africans.

Blood 121 (16), 3254-3260 (2013).


Bolt G, Vandahl BBS, Thim L, Stennicke HR, Steenstrup TD, Defrees S.

Conjugated Factor VIII molecules.

US Pat Appl 20130137638 (2013).


Fenger-Eriksen C, Christiansen K, Laurie J, Sörensen B, Rea C.

Fibrinogen concentrate and cryoprecipitate but not fresh frozen plasma correct low fibrinogen concentrations following in vitro haemodilution.

Thromb Res  131 (5), 210-213 (2013).


Pahl S, Pavlova A, Driesen J, Müller J, Pötzsch B, Oldenburg J.

In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile

Haemophilia 19 (3), 392-398 (2013).


Traby L, Kollars M, Eischer L, Eichinger S, Kyrle PA.

Prediction of recurrent venous thromboembolism by clot lysis Time: A prospective cohort study.

PLoS ONE 7(12): e51447. doi:10.1371/journal.pone.0051447 (2012).


De Lange Z, Pieters M, Jerling, Kruger A, Rijken DC.

Plasma clot lysis time and its association with cardiovascular risk factors in black Africans.

PLoS ONE 7(11): e48881. doi:10.1371/journal.pone.0048881 (2012).


Larsen CC, Sörensen B, Nielsen JD, Astrup J.

Reduced clot-stability during the first 6 hours after aneurysmal subarachnoid haemorrhage – a prospective case-control study.

Thromb Res  129 (5), 229-232 (2012).


Sandberg H, Kannicht C, Stenlund P, Dadaian M, Oswaldsson U, Cordula C, Walter O.

Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.

Thromb Res 130 (5), 808-817 (2012).


De Wee EM, Eikenboom K HC,Van der Bom JG, Fijnvandraat K, Laros Van Gorkom B, Mauser-Bunschoten EP et al. for the WIN Study Group.

Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease.

Haemophilia 18 (3), 444-451 (2012).


Cellai AP, Lami D, Fedi S, Marcucci R, Mannini L, Cenci C, Rogolino A et al.

A hypercoagulable and hypofibrinolytic state is detectable by global methods in patients with retinal vein occlusion.

Atherosclerosis 224 (1), 97-101 (2012).


Winckers K, Siegerink B, Duckers C, Maurissen LF, Tans GT , Castoldi E, Spronk HMH et al.

Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study.

J Thromb Haemost  9 (11), 2243-2250 (2011).


Castoldi E, Duckers C, Radu C, Spiezia L, Rossetto V, Tagariello G, Rosing J, Simioni P.

Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma.

J Thromb Haemost  9 (5), 959-968 (2011).


Blombäck M, He S, Bark N, Wallén HN, Elg M.

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate.

Br J Haematol 152 (6), 758-765 (2011).


Loof TG, Mörgelin M, Johansson L, Oehmce S, Olin AI, Dickneite G, Norrby-Teglund A, Theopold U, Herwald H.

Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense.

Blood 118 (9), 2589-2598 (2011).


Skeppholm M, Kallner A, Malmqvist K, Blombäck M, Wallén.

Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?

Thromb Res 128 (5), 483-489 (2011).

Adams GN, La Rusch GA, Stavrou E, Zhou Y, Nieman MT, Jacobs GH, Schmaier AH et al.

Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis.

Blood 117 (14), 3929-3937 (2011).


Christiansen MLS, Balling KW, Persson E, Hilden I, Bagger-Sörensen A, Sörensen BB, Viuff D et al. Functional characteristics of N8, a new recombinant FVIII.

Haemophilia 16 (6), 878-887 (2010)


Christensen TD, Jensen C, Larsen TB, Maegaard M, Christiansen K, Sörensen B.

International Normalized Ratio (INR), coagulation factor activities and calibrated automated thrombin generation - influence of 24 h storage at ambient temperature.

Int J Lab Hematol  32 (2), 206-214 (2010).


Duckers C, Simioni P, Spiezia L, Radu C, Dabrilli P, Gavasso S, Rosing, Castoldi E.

Residual platelet factor V ensures thrombin generation in patients with severe congenital factor V deficiency and mild bleeding symptoms.

Blood 115 (4), 879-88 (2010).


Barklin A, Tönnesen E, Ingerslev J, Sörensen B, Fenger-Ericsen C.

Coagulopathy during induced severe intracranial hypertension in a porcine donor model.

Anesthesiology 110 (6), 1287-1292 (2009).


Fiore MM, Mackie IJ.

Dual effect of platelet factor 4 on the activities of factor Xa.

Biochem Biophys Res Commun 370 (4), 1072-1075 (2009).


Fenger-Ericsen C, Jensen TM, Kristensen BS, Jensen KM, Tönnesen E, Ingerslev J, Sörensen B.

Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial.

J Thromb Haemost 7 (5), 795-802 (2009).


Christensen TD, Jensen C, Larsen TB, Christiansen K, Sörensen B.

Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio.

Blood Coag Fibrinol 20 (5), 358-365 (2009).


Tchaikovski SN, Van Vlijmen BJM, Cleuren ACA, Thomassen MCLGD, Tchaikovski V, Tans G, Rosing J.

Pregnancy-associated changes in the hemostatic system in wild-type and factor V Leiden mice.

J Thromb Haemost 7 (2), 312-318 (2009).


Devreese K, Peerlinck K, Arnout J, Hoylaerts M.

Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography.

Thromb Haemost 101 (1), 185-196 (2009).


Dielis AWJH, Castoldi E, Spronk HMH, Van Oerle R, Hamulyák K, Ten Cate H, Rosing J.

Coagulation factors and the protein C system as determinants of thrombin generation in a normal population.

J Thromb Haemost 6 (1), 125-131 (2008).


Gardiner C, Machin SJ, Mackie IJ.

Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000).

Int J Lab Hematol 30 (4), 261-268 (2008).


Tchaikovski SN, Van Vlijmen BJM, Rosing J, Tans G.

Development of a calibrated automated thrombography based thrombin generation test in mouse plasma.

J Thromb Haemost 5 (10), 2079-2086 (2007).


Li N, He S, Blombäck M, Hjemdahl P.

Platelet activity, coagulation and fibrinolysis during exercise in healthy males. Effects of thrombin inhibition by argatroban and enoxaparin.

Arterioscl Thromb Vasc Biol  27, 407-413 (2007).


Gardiner C, Cohen H, Austin SK, Machin SJ, Mackie IJ.

Pregnancy loss, tissue factor pathway inhibitor deficiency and resistance to activated protein C.

J Thromb Haemost 4 (12), 2724-2726 (2006).


2019-06-20 ISTH, Melbourne July 6-10, 2019.

Rossix will present three posters related to analysis of Factor IX at the ISTH in Melbourne:

PB0099 - Evaluation of Lupus Anticoagulant interference in a chromogenic Factor IX kit for determination of

Factor IX activity

PB1294 - Assessment of Factor IX Padua activity with a one-stage clotting method and with FXIa- and tissue factor/FVIIa-based chromogenic methods

PB1295 - Recombinant Factor IX fused with albumin (rFIX-HSA) is underassigned by one-stage methods with silica as contact activator

More information


2016-06-22 Publication in collaboration with NovoNordisk

Rosén P, Rosén S, Ezban M, Persson E.

Overestimation of N-glycoPEGylated factor IX activity in one-stage factor IX clotting assay owing to silica-mediated premature conversion to activated factor IX.

J Thromb Haemost 2016; 14: 1420-7.


2015-04-13 Publication in collaboration with AstraZeneca

Ann Lövgren et al. Blood Coagulation and Fibrinolysis, Characterization of thrombin derived from 

human recombinant prothrombin.

Open access: click here